Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

ALLR

Allarity Therapeutics Inc

Apr 17 • 04:00PM ET

1.50

Dollar change -0.18
Percentage change -10.71	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4117.54	Insider Own	10.59%	Shs Outstand	0.47M	Perf Week	-53.56%
Market Cap	0.70M	Forward P/E	-	EPS next Y	-30.40	Insider Trans	0.00%	Shs Float	0.42M	Perf Month	-78.57%
Income	-20.42M	PEG	-	EPS next Q	-10.60	Inst Own	0.62%	Short Float	6.01%	Perf Quarter	-84.54%
Sales	0.00M	P/S	-	EPS this Y	86.06%	Inst Trans	-	Short Ratio	0.06	Perf Half Y	-89.51%
Book/sh	-15.26	P/B	-	EPS next Y	-6.29%	ROA	-90.14%	Short Interest	0.03M	Perf Year	-99.84%
Cash/sh	0.36	P/C	4.15	EPS next 5Y	-	ROE	-20995.16%	52W Range	1.62 - 2520.00	Perf YTD	-86.39%
Dividend Est.	-	P/FCF	-	EPS past 5Y	57.56%	ROI	-	52W High	-99.94%	Beta	0.47
Dividend TTM	-	Quick Ratio	0.14	Sales past 5Y	-25.00%	Gross Margin	-	52W Low	-7.41%	ATR (14)	0.80
Dividend Ex-Date	-	Current Ratio	0.14	EPS Y/Y TTM	93.27%	Oper. Margin	0.00%	RSI (14)	10.70	Volatility	40.81% 23.21%
Employees	6	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	8.00
Option/Short	No / No	LT Debt/Eq	-	EPS Q/Q	99.91%	Payout	-	Rel Volume	2.43	Prev Close	1.68
Sales Surprise	-	EPS Surprise	78232.00%	Sales Q/Q	-	Earnings	Mar 08 BMO	Avg Volume	444.72K	Price	1.50
SMA20	-68.71%	SMA50	-77.85%	SMA200	-92.69%	Trades		Volume	1,081,380	Change	-10.71%

Apr-17-24 09:10AM	Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1) (GlobeNewswire) -10.71%
Apr-12-24 08:18AM	Why Is Allarity Therapeutics (ALLR) Stock Up 41% Today? (InvestorPlace) -8.58%
Apr-04-24 09:15AM	Allarity Therapeutics Announces 1-for-20 Reverse Stock Split (GlobeNewswire) +5.78%
Mar-27-24 08:30AM	Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer (GlobeNewswire)
Mar-25-24 07:30AM	Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1) (GlobeNewswire) -12.25%
07:15AM	Loading…
Mar-08-24 07:15AM	Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Feb-28-24 06:00AM	Allarity Therapeutics to Present at Biomarkers 2024 (GlobeNewswire) +8.06%
Dec-12-23 06:00AM	Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor (GlobeNewswire)
Dec-05-23 10:07AM	Why Is Allarity Therapeutics (ALLR) Stock Up 42% Today? (InvestorPlace)
07:30AM	Allarity's Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP Companion Diagnostic (GlobeNewswire)
Oct-02-23 07:00AM	Allarity Therapeutics to Present at Biomarkers Europe 2023 (GlobeNewswire)
Sep-14-23 09:25AM	Allarity Therapeutics Gaining Momentum? Hits Multiple Milestones Including Positive Publications In PLOS One And At ASCO, Positive Early Data From An Ongoing Clinical Trial, And External Partnering For Its DRP(R) Technology (ACCESSWIRE)
Aug-30-23 04:05PM	PLOS ONE Publishes Data on Allarity Therapeutics DRP® Companion Diagnostic for Dovitinib (GlobeNewswire)
Jul-31-23 06:00AM	Allarity Therapeutics and FivepHusion Announce Collaboration to Support Clinical Development of Deflexifol with DRP® Companion Diagnostics (GlobeNewswire)
Jul-24-23 06:00AM	Allarity Therapeutics Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives (GlobeNewswire)
04:00AM	Loading…
Jul-12-23 04:00AM	ALLR: IXEMPRA Clinical Update (Zacks)
Jul-06-23 06:00AM	Allarity Therapeutics, Inc. Announces Pricing of $11 Million Public Offering (GlobeNewswire) -53.99%
Jul-05-23 09:45AM	Initial Data from Allaritys Phase 2 Trial of IXEMPRA® Indicate Potential for Improved Clinical Benefit in DRP®-Selected Metastatic Breast Cancer Patients (GlobeNewswire) +31.43%
Jun-28-23 11:55AM	Allarity Therapeutics Announces Reverse Stock Split of Common Stock (GlobeNewswire) +16.01%
Jun-27-23 06:16PM	Allarity Therapeutics Announces Clarification of Effective Date for Reverse Stock Split (GlobeNewswire)
Jun-20-23 04:05PM	Allarity Therapeutics Announces Adjournment of Special Meeting of Stockholders (GlobeNewswire)
May-30-23 06:00AM	First Prospective Clinical Validation of Allarity's DRP® Companion Diagnostic to be Presented at 2023 ASCO Annual Meeting (GlobeNewswire) -16.13%
Apr-27-23 09:00AM	Allarity Therapeutics Accelerates Trial Enrollment To Bring FDA-Approved Breast Cancer Treatment To European Market - Interim Results Could Be Released In Second Half Of 2023 (ACCESSWIRE) +8.50%
Apr-19-23 09:18AM	Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering (GlobeNewswire) -43.54%
Apr-17-23 09:00AM	This Combination Therapy Could Help Change Cancer Treatment - Take A Deeper Look Into Allarity Therapeutics' Trial (ACCESSWIRE) -18.06%
05:24AM	ALLR: Clinical Update (Zacks Small Cap Research)
Apr-16-23 06:30AM	7 Sorry Pharma Stocks to Sell in April Before Its Too Late (InvestorPlace)
Apr-11-23 07:00AM	Abstract Evaluating Allaritys DRP® Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting (GlobeNewswire)
Mar-31-23 05:15AM	ALLR: March Clinical Update (Zacks Small Cap Research)
Mar-28-23 09:12AM	Allarity Outlines Steps To Accelerate Delayed Recruitment In Ixempra, Stenoparib Cancer Trials (Benzinga) -17.90%
06:00AM	Loading…
06:00AM	Allarity Therapeutics Provides Updates for IXEMPRA and Stenoparib Phase 2 Monotherapy Clinical Studies (GlobeNewswire)
Mar-24-23 06:00AM	Allarity Therapeutics Announces Reverse Stock Split of Common Stock (GlobeNewswire) -31.95%
Mar-20-23 06:00AM	Allarity Therapeutics Doses First Patient in Phase 1b Clinical Trial Evaluating Dovitinib and Stenoparib Combination in Advanced Solid Tumors (GlobeNewswire) +37.05%
Jan-31-23 07:54AM	6 F-Rated Penny Stocks Not Worth Your Dime (InvestorPlace)
Jan-20-23 04:01PM	Allarity Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders (GlobeNewswire) +16.16%
Dec-01-22 04:25PM	Allarity Therapeutics Reschedules 2022 Annual Stockholders Meeting and Sets New Record Date (GlobeNewswire)
Nov-15-22 04:01PM	Allarity Therapeutics Reports Third Quarter 2022 Financial Results (GlobeNewswire) -9.04%
Nov-07-22 06:15PM	Allarity Therapeutics Announces Adjournment of 2022 Annual Meeting of Stockholders (GlobeNewswire) -5.19%
Oct-18-22 08:00AM	Precision Medicine Could Get Even More Precise With Allarity Therapeutics Next-Generation Diagnostics Platform (News Direct) +5.11%
Oct-11-22 04:05PM	Allarity Therapeutics Reports Second Quarter 2022 Financial Results, Provides Recent Operational Highlights, and Regains Compliance with NASDAQ Listing Requirements (GlobeNewswire)
Sep-26-22 06:00AM	Allarity Therapeutics Appoints Seasoned Biotechnology Executive Jerry McLaughlin to Board of Directors (GlobeNewswire)
Sep-16-22 06:00AM	Allarity Therapeutics to Present at Ladenburg Thalmann Healthcare Conference (GlobeNewswire)
Sep-13-22 05:20AM	ALLR: A Precision Undertaking (Zacks Small Cap Research) +8.61%
Sep-12-22 04:10PM	Allarity Therapeutics Announces Appointment of New Auditor (GlobeNewswire)
Aug-26-22 04:30PM	Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1) (GlobeNewswire)
Aug-02-22 06:00AM	Allarity Therapeutics Refocuses Oncology Pipeline Strategy Towards Combination Therapies (GlobeNewswire)
Jul-11-22 07:00AM	Allarity Therapeutics Bolsters Its Board of Directors with Appointment of Prominent Clinical Researcher and Oncology Drug Developer, David A. Roth, M.D. (GlobeNewswire)
Jun-29-22 04:01PM	Allarity Therapeutics Announces Executive Leadership Transition (GlobeNewswire) -11.41%
Jun-15-22 09:25AM	Allarity Therapeutics Strengthens Scientific Advisory Board with Appointment of Distinguished Oncologist Roberto Pili, M.D. (GlobeNewswire)
May-27-22 05:37PM	Allarity Therapeutics Reports First Quarter 2022 Financial Results (GlobeNewswire) +39.32%
May-18-22 05:30PM	Correction Notice to Press Release Announcing Financial Results For the Fourth Quarter and Full Year 2021 Financial Results and Corporate Update (GlobeNewswire)
May-16-22 07:40PM	Allarity Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update (GlobeNewswire)
Apr-22-22 05:00PM	Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1) (GlobeNewswire)
Mar-15-22 08:32AM	Allarity Therapeutics Provides Update on Dovitinib Program (GlobeNewswire)
Feb-18-22 04:15PM	Allarity Therapeutics Receives Refusal to File Letters from U.S. FDA (GlobeNewswire)
Jan-21-22 02:30AM	Nasdaqs European Markets Delivered Record Year in 2021 (GlobeNewswire)
Jan-03-22 08:00AM	Allarity Therapeutics and Oncoheroes Biosciences Sign Agreements to Advance Pediatric Cancer Development of Dovitinib and Stenoparib (GlobeNewswire)
Dec-22-21 08:00AM	Allarity Therapeutics Submits New Drug Application (NDA) to the U.S. FDA for Dovitinib for Third-Line Treatment of Renal Cell Carcinoma (RCC) (GlobeNewswire) +20.24%
Dec-21-21 08:00AM	Allarity Therapeutics Closes Its Recapitalization, Share Exchange, and $20M PIPE Investment; Lists on U.S. Nasdaq Stock Market (GlobeNewswire)

Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company operates in two geographic areas: Denmark and the United States. The company was founded on April 4, 2021 and is headquartered in Boston, MA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALLR

Allarity Therapeutics Inc

Upgrade your FINVIZ experience